Differences in replication kinetics and cell tropism between neurovirulent and non-neurovirulent EHV1 strains during the acute phase of infection in horses

Veterinary Microbiology

Volumn 142, Issue 3-4, 2010, Pages 242-253

  Gryspeerdt, Annick C ^a   Vandekerckhove, A P ^a   Garre B ^a   Barbe F ^a   Van de Walle, G R ^a   Nauwynck, H J ^a  

^a GHENT UNIVERSITY   (Belgium)

Author keywords

Carrier cells; EHV1; Pathogenesis; Strain differences

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; EQUINE HERPES VIRUS; HERPES VIRUS INFECTION; HISTOPATHOLOGY; HORSE; LYMPH NODE; LYMPHOCYTE COUNT; MALE; NASOPHARYNX; NONHUMAN; STRAIN DIFFERENCE; UPPER RESPIRATORY TRACT; VIREMIA; VIROGENESIS; VIRUS REPLICATION; VIRUS SHEDDING; VIRUS VIRULENCE;

ANIMALS; ANTIBODIES, VIRAL; CELL LINE; EPITHELIUM; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 1, EQUID; HORSE DISEASES; HORSES; MALE; RABBITS; RESPIRATORY SYSTEM; VIREMIA; VIRUS REPLICATION;

EQUID HERPESVIRUS 1; EQUIDAE;

EID: 77952098490     PISSN: 03781135     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vetmic.2009.10.015     Document Type: Article

References (42)

1. Ahn J.S., Konno A., Gebe J.A., Aruffo A., Hamilton M.J., Park Y.H., Davis W.C. Scavenger receptor cysteine-rich domains 9 and 11 of WC1 are receptors for the WC1 counter receptor. J. Leukoc. Biol. 2002, 72:382-390.
2. Allen G.P., Breathnach C.C. Quantification by real-time PCR of the magnitude and duration of leucocyte-associated viraemia in horses infected with neuropathogenic vs. non-neuropathogenic strains of EHV-1. Equine Vet. J. 2006, 38:252-257.
3. Allen G.P., Bryans J.T. Molecular epizootiology, pathogenesis, and prophylaxis of equine herpesvirus-1 infections. Prog. Vet. Microbiol. Immunol. 1986, 2:78-144.
4. Bosnjak L., Jones C.A., Abendroth A., Cunningham A.L. Dendritic cell biology in herpesvirus infections. Viral Immunol. 2005, 18:419-433.
5. Bridges C.G., Edington N. Innate immunity during equid herpesvirus 1 (EHV-1) infection. Clin. Exp. Immunol. 1986, 65:172-181.
6. Cornick J., Martens J., Martens R., Crandell R., McConnell S., Kit S. Safety and efficacy of a thymidine kinase negative equine herpesvirus-1 vaccine in young horses. Can. J. Vet. Res. 1990, 54:260-266.
7. Edington N., Bridges C.G., Griffiths L. Equine interferons following exposure to equid herpesvirus-1 or -4. J. Interferon. Res. 1989, 9:389-392.
8. Edington N., Bridges C.G., Patel J.R. Endothelial cell infection and thrombosis in paralysis caused by equid herpesvirus-1: equine stroke. Arch. Virol. 1986, 90:111-124.
9. Fu Y.X., Chaplin D.D. Development and maturation of secondary lymphoid tissues. Annu. Rev. Immunol. 1999, 17:399-433.
10. Garre B., Gryspeerdt A., Croubels S., De Backer P., Nauwynck H. Evaluation of orally administered valacyclovir in experimentally EHV1-infected ponies. Vet. Microbiol. 2009, 135:214-221.
11. Glorieux S., Favoreel H.W., Meesen G., de Vos W., Van den Broeck W., Nauwynck H.J. Different replication characteristics of historical pseudorabies virus strains in porcine respiratory nasal mucosa explants. Vet. Microbiol. 2009, 136:341-346.
12. Goehring L.S., van Winden S.C., van Maanen C., Sloet van Oldruitenborgh-Oosterbaan M.M. Equine herpesvirus type 1-associated myeloencephalopathy in The Netherlands: a four-year retrospective study (1999-2003). J. Vet. Intern. Med. 2006, 20:601-607.
13. Goodman L.B., Wagner B., Flaminio M.J., Sussman K.H., Metzger S.M., Holland R., Osterrieder N. Comparison of the efficacy of inactivated combination and modified-live virus vaccines against challenge infection with neuropathogenic equine herpesvirus type 1 (EHV-1). Vaccine 2006, 24:3636-3645.
14. Goodman L.B., Loregian A., Perkins G.A., Nugent J., Buckles E.L., Mercorelli B., Kydd J.H., Palu G., Smith K.C., Osterrieder N., Davis-Poynter N. A point mutation in a herpesvirus polymerase determines neuropathogenicity. PLoS Pathog. 2007, 3:1583-1592.
15. Greenwood R.E., Simson A.R. Clinical report of a paralytic syndrome affecting stallions, mares and foals on a thoroughbred studfarm. Equine Vet. J. 1980, 12:113-117.
16. Heldens J.G., Hannant D., Cullinane A.A., Prendergast M.J., Mumford J.A., Nelly M., Kydd J.H., Weststrate M.W., van den Hoven R. Clinical and virological evaluation of the efficacy of an inactivated EHV1 and EHV4 whole virus vaccine (Duvaxyn EHV1, 4). Vaccination/challenge experiments in foals and pregnant mares. Vaccine 2001, 19:4307-4317.
17. Jackson T.A., Osburn B.I., Cordy D.R., Kendrick J.W. Equine herpesvirus 1 infection of horses: studies on the experimentally induced neurologic disease. Am. J. Vet. Res. 1977, 38:709-719.
18. Kydd J.H., Smith K.C., Hannant D., Livesay G.J., Mumford J.A. Distribution of equid herpesvirus-1 (EHV-1) in the respiratory tract of ponies: implications for vaccination strategies. Equine Vet. J. 1994, 26:466-469.
19. Matsumura T., O'Callaghan D.J., Kondo T., Kamada M. Lack of virulence of the murine fibroblast adapted strain, Kentucky A (KyA), of equine herpesvirus type 1 (EHV-1) in young horses. Vet. Microbiol. 1996, 48:353-365.
20. McCartan C.G., Russell M.M., Wood J.L., Mumford J.A. Clinical, serological and virological characteristics of an outbreak of paresis and neonatal foal disease due to equine herpesvirus-1 on a stud farm. Vet. Rec. 1995, 136:7-12.
21. Mumford J.A., Edington N. EHV1 and equine paresis. Vet. Rec. 1980, 106:277.
22. Novak N., Peng W.M. Dancing with the enemy: the interplay of herpes simplex virus with dendritic cells. Clin. Exp. Immunol. 2005, 142:405-410.
23. Nugent J., Birch-Machin I., Smith K.C., Mumford J.A., Swann Z., Newton J.R., Bowden R.J., Allen G.P., Davis-Poynter N. Analysis of equid herpesvirus 1 strain variation reveals a point mutation of the DNA polymerase strongly associated with neuropathogenic versus nonneuropathogenic disease outbreaks. J. Virol. 2006, 80:4047-4060.
24. Ostlund E.N. The equine herpesviruses. Vet. Clin. North Am. Equine Pract. 1993, 9:283-294.
25. Patel J.R., Edington N., Mumford J.A. Variation in cellular tropism between isolates of equine herpesvirus-1 in foals. Arch. Virol. 1982, 74:41-51.
26. Pollara G., Kwan A., Newton P.J., Handley M.E., Chain B.M., Katz D.R. Dendritic cells in viral pathogenesis: protective or defective?. Int. J. Exp. Pathol. 2005, 86:187-204.
27. Randolph G.J., Ochando J., Partida-Sanchez S. Migration of dendritic cell subsets and their precursors. Annu. Rev. Immunol. 2008, 26:293-316.
28. Reed L.J., Muench H. A simple method of estimating fifty per cent endpoints. Am. J. Hyg. 1938, 27:493-497.
29. Scott J.C., Dutta S.K., Myrup A.C. In vivo harboring of equine herpesvirus-1 in leukocyte populations and subpopulations and their quantitation from experimentally infected ponies. Am. J. Vet. Res. 1983, 44:1344-1348.
30. Siedek E.M., Whelan M., Edington N., Hamblin A. Equine herpesvirus type 1 infects dendritic cells in vitro: stimulation of T lymphocyte proliferation and cytotoxicity by infected dendritic cells. Vet. Immunol. Immunopathol. 1999, 67:17-32.
31. Steinbach F., Borchers K., Ricciardi-Castagnoli P., Ludwig H., Stingl G., Elbe-Burger A. Dendritic cells presenting equine herpesvirus-1 antigens induce protective anti-viral immunity. J. Gen. Virol. 1998, 79:3005-3014.
32. Stierstorfer B., Eichhorn W., Schmahl W., Brandmuller C., Kaaden O.R., Neubauer A. Equine herpesvirus type 1 (EHV-1) myeloencephalopathy: a case report. J. Vet. Med. B: Infect. Dis. Vet. Public Health 2002, 49:37-41.
33. Tew J.G., Kosco M.H., Burton G.F., Szakal A.K. Follicular dendritic cells as accessory cells. Immunol. Rev. 1990, 117:185-211.
34. Tumas D.B., Brassfield A.L., Travenor A.S., Hines M.T., Davis W.C., McGuire T.C. Monoclonal antibodies to the equine CD2 T-lymphocyte marker, to a pan-granulocyte monocyte marker and to a unique pan-B lymphocyte marker. Immunobiology 1994, 192:48-64.
35. Van de Walle G.R., Goupil R., Wishon C., Damiani A., Perkins G.A., Osterrieder N. A single-nucleotide polymorphism in a herpesvirus DNA polymerase is sufficient to cause lethal neurological disease. J. Infect. Dis. 2009, 200:20-25.
36. van der Meulen K.M., Gryspeerdt A.C., Vandekerckhove A.A., Garre B.A., Nauwynck H.J. The protective properties of vaccination against equine herpesvirus 1-induced viremia, abortion and nervous system disorders. Vlaams Diergen Tijds 2007, 76:186-194.
37. van der Meulen K., Caij B., Pensaert M., Nauwynck H. Absence of viral envelope proteins in equine herpesvirus 1-infected blood mononuclear cells during cell-associated viremia. Vet. Microbiol. 2006, 113:265-273.
38. van der Meulen K., Vercauteren G., Nauwynck H., Pensaert M. A local epidemic of equine herpesvirus 1-induced neurological disorders in Belgium. Vlaams Diergen Tijds 2003, 72:366-372.
39. van der Meulen K.M., Nauwynck H.J., Buddaert W., Pensaert M.B. Replication of equine herpesvirus type 1 in freshly isolated equine peripheral blood mononuclear cells and changes in susceptibility following mitogen stimulation. J. Gen. Virol. 2000, 81:21-25.
40. van der Meulen K.M., Nauwynck H.J., Pensaert M.B. Mitogen stimulation favours replication of equine herpesvirus-1 in equine blood mononuclear cells by inducing cell proliferation and formation of close intercellular contacts. J. Gen. Virol. 2001, 82:1951-1957.
41. van der Meulen K.M., Nauwynck H.J., Pensaert M.B. Absence of viral antigens on the surface of equine herpesvirus-1-infected peripheral blood mononuclear cells: a strategy to avoid complement-mediated lysis. J. Gen. Virol. 2003, 84:93-97.
42. van Maanen C. Equine herpesvirus 1 and 4 infections: an update. Vet. Q. 2002, 24:58-78.